EOLS — Evolus, Inc. stock price, charts and financials

QT80Evolus, Inc.

Evolus, Inc. (NASDAQ: EOLS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
7.57
-0.02-0.26%
OverviewShort InterestFilings
EOLSQT80Evolus, Inc.·NASDAQ
7.57-0.26%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AQST+8.88%$4.29KMDA-1.79%$7.14TLRY-3.28%$4.42IRWD-6.25%$4.05EVO+4.00%$2.08AMPH-2.26%$20.31COLL-7.70%$27.20PCRX-2.36%$24.43
Snapshot
Index-P/E-EPS (ttm)-0.92Insider Own-Shs Outstand65.85MPerf Week29.97%
Market Cap499.84MForward P/E33.63EPS next Y0.23Insider Trans-0.45%Shs Float50.04MPerf Month10.80%
Enterprise Value619.47MPEG-EPS next Q-Inst Own-Short Float11.80%Perf Quarter18.78%
Income-34.29MP/S1.58EPS this Y88.90%Inst Trans-Short Ratio6.99Perf Half Y72.11%
Sales316.49MP/B-EPS next Y321.03%ROA-13.84%Short Interest5.91MPerf YTD14.14%
Book/sh-P/C-EPS next 5Y-ROE123.11%52W High7.93 -4.53%Perf Year19.15%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-15.27%52W Low3.85 96.63%Perf 3Y-22.87%
Dividend Est.-EV/EBITDA-Sales past 3/5Y25.85% 39.12%Gross Margin66.25%Volatility7.06% 5.72%Perf 5Y-29.85%
Dividend TTM-EV/Sales1.96EPS Y/Y TTM-13.58%Oper. Margin-7.33%ATR (14)0.39Perf 10Y-
Dividend Ex-Date-Quick Ratio1.28Sales Y/Y TTM7.52%Profit Margin-10.85%RSI (14)72.29Recom2.15
Dividend Gr. 3/5Y-Current Ratio1.70EPS Q/Q44.44%SMA2023.45%Beta1.42Target Price18.40
Payout0.00%Debt/Eq-Sales Q/Q5.80%SMA5016.90%Rel Volume2.05Prev Close7.59
Employees334LT Debt/Eq-6.61EarningsNov 04SMA20028.92%Avg Volume795.07KPrice7.57
IPO DateFeb 08, 2018Option/ShortYes / YesEPS/Sales Surpr.6.86% 0.85%Net Debt/EBITDA-11.69Volume1,630,868Change-0.26%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-04-26ReiteratedMizuho SecuritiesOutperform$19 → $15
Jan-22-26ReiteratedBTIGBuy$13
Jan-13-26ReiteratedStifel Nicolaus$20 → $17
Aug-06-25DowngradeNeedhamBuy → Hold
Oct-03-24ReiteratedHC Wainwright & Co.Buy$27
Sep-13-24ReiteratedMizuho SecuritiesBuy$25
Sep-13-24ReiteratedBarclaysOverweight$16 → $20
Jan-29-24UpgradeBarclaysEqual Weight → Overweight$16
May-13-22UpgradeBarclaysUnderweight → Equal Weight
May-12-22UpgradeBarclaysUnderweight → Equal Weight
Latest News
Aug-06-26
Aug-06-2606:02PM
Evolus, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
12:30AM
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-05-26
Aug-05-2609:37PM
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2zacks.com
09:04PM
Evolus Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlookbusinesswire.com
Aug-04-26
Aug-04-2609:00AM
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealandgurufocus.com
Jul-22-26
Jul-22-2608:30AM
Evolus to Report Second Quarter Financial Results on August 5, 2026businesswire.com
Jul-10-26
Jul-10-2604:05PM
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Jul-08-26
Jul-08-2609:03AM
Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In USBenzinga
09:00AM
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Qualitybusinesswire.com
Jun-17-26
Jun-17-2606:04AM
BTIG Reiterates Buy on Evolus, Maintains $13 Price TargetBenzinga
Company

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue286297266——————
Cost of Goods Sold Incl. D&A9810484——————
Gross Profit188193182——————
Selling, General and Administrative Excl. Other217221198——————
Research and Development8109——————
Other Operating Expense3-110——————
Operating Income-38-38-34——————
Interest Expense202019——————
Unusual Expense
—————————
Non-Operating Income (Expense)263——————
Net Income Before Taxes-58-51-50——————
Income Taxes011——————
Consolidated Net Income-59-52-50——————
Net Income From Continuing Operations-59-52-50——————
Net Income-59-52-50——————
EPS (Recurring)-0.92-0.80-0.81——————
EPS (Basic, Before Extraordinaries)-0.92-0.80-0.81——————
EPS (Diluted)-0.92-0.80-0.81——————
EBITDA-30-23-25——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio1.721.432.57——————
Gross Margin65.7364.9868.42——————
Operating Margin-13.29-12.79-12.78——————
Net Margin-20.63-17.51-18.80——————
Shares Outstanding656462——————
Market Capitalization492426684——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$11.19$9.14$7.09$5.04$2.99● Close Price0.00K199.23K398.47K597.70K796.93KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
MOATAZEDI DAVIDSee RemarksMar 20 '26Sale4.7513,66964,929604,700Mar 20
Avelar RuiSee RemarksMar 20 '26Sale4.753,11914,815427,423Mar 20
MOATAZEDI DAVIDSee RemarksMar 17 '26Sale4.89116,720570,562618,369Mar 18
Avelar RuiSee RemarksMar 17 '26Sale4.8929,996146,629430,542Mar 18
MOATAZEDI DAVIDSee RemarksMar 16 '26Option Exercise0.0067,4890735,089Mar 18
Avelar RuiSee RemarksMar 16 '26Option Exercise0.008,8040460,538Mar 18
MOATAZEDI DAVIDSee RemarksDec 22 '25Sale7.1510,53975,361354,388Dec 29
Avelar RuiSee RemarksDec 22 '25Sale7.152,26116,168356,821Dec 29
Yamagishi-Dressler TomokoChief Marketing OfficerAug 22 '25Sale7.515,72242,97289,949Aug 26
Stewart BradyDirectorAug 15 '25Buy6.8230,000204,48688,629Aug 18
MOATAZEDI DAVIDSee RemarksJun 16 '25Sale9.8916,582164,054364,927Jun 16
MOATAZEDI DAVIDSee RemarksJun 13 '25Sale10.05111,3231,119,141381,509Jun 16
White Albert G IIIDirectorJun 09 '25Buy9.4520,000189,00050,378Jun 10
Beaver SandraChief Financial OfficerMay 13 '25Sale10.026,49465,070167,089May 14
Avelar RuiSee RemarksMay 12 '25Sale9.873,38533,397359,082May 14
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.